Autolus Therapeutics company information, Employees & Contact Information

1,093,300 Options: Autolus Grants Inducement Awards at $1.49, four-year vesting to new hires Stock Titan

Autolus Therapeutics Announces Upcoming Presentation at ACR Convergence 2025 on CARLYSLE Study Results for Severe Refractory Systemic Lupus Erythematosus Quiver Quantitative

Autolus Therapeutics plc Announces Q2 2025 Financial Results Release Date and Conference Call Details Nasdaq

Autolus Therapeutics: Beaten Down, Cash Rich, Poised To Launch A CAR-T Cell Therapy (NASDAQ:AUTL) Seeking Alpha

First patient dosed in Phase 1 BOBCAT trial — Autolus advances obe-cel for progressive MS (up to 18 patients) Stock Titan

Autolus Therapeutics Grants Stock Options to 60 Employees Under 2025 Inducement Plan | AUTL Stock News Quiver Quantitative

Autolus Therapeutics to Report Second Quarter 2025 Financial Results and Host Conference Call on August 12, 2025 The Manila Times

Autolus Therapeutics Reports Q2 2025 Revenue of $20.9 Million and Receives Conditional Marketing Approvals for AUCATZYL® in the UK and EU Quiver Quantitative

Early-Stage T Cell Therapy Leader Autolus Sets Q2 Earnings Date: Key Updates Expected Stock Titan

European Commission Grants Marketing Authorization for Autolus Therapeutics' AUCATZYL® (obecabtagene autoleucel) to Treat Adult Patients with Relapsed or Refractory B-ALL Nasdaq

UCL spinout Autolus gains US approval for cancer therapy | UCL News - UCL University College London

‘Serial Killing’ Cell Therapy From Autolus Lands FDA Approval in Blood Cancer MedCity News

Autolus Therapeutics Provides Business Updates and 2025 Overview The Manila Times

Zero Grade 2+ Side Effects: Autolus' Revolutionary CAR-T Treatment Shows Promise in Lupus Patients Stock Titan

Autolus Awards Massive Stock Options Package: 360K Shares Granted to 60 New Employees Under Nasdaq Rule Stock Titan

Autolus Therapeutics Reports First Quarter 2025 Financial Results and Business Updates Stock Titan

Autolus (NASDAQ: AUTL) notes no ICANS, high-grade CRS; 83% in remission and 50M dose set Stock Titan

Autolus doses first participant in obe-cel trial for progressive MS Clinical Trials Arena

BioNTech bails out Autolus | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Autolus Therapeutics: Expanding The Reach Of Its CD19 Therapy, But Still Far From Profitable Seeking Alpha

Autolus readies its CAR-T Aucatzyl to go after heavy hitter competition following FDA nod Fierce Pharma

BioNTech passes on Autolus' CD19/CD22 CAR-T amid pipeline prioritization Fierce Biotech

Autolus: A Buy Before Key Data Readout, Potential Expansion Into Autoimmune Market (AUTL) Seeking Alpha

Autolus Therapeutics Announces Updated Manufacturing Facility Strategy Leveraging its UK Operations Yahoo Finance

Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MarketScreener

Autolus Therapeutics announces retirement of chief financial officer and succession plan Yahoo Finance

UCL spinout Autolus gains UK licence for cancer therapy | UCL News - UCL University College London

Blackstone Life Sciences to invest up to $250 million in GlobeNewswire

Autolus Therapeutics Will Remain Depressed For A While (NASDAQ:AUTL) Seeking Alpha

MHRA approves Autolus Therapeutics’ Aucatzyl to treat acute lymphoblastic leukaemia PMLiVE

BioNTech pays Autolus $250M for manufacturing, CAR-T expertise in wide-ranging collab Fierce Biotech

AUTL Stock Price and Chart — NASDAQ:AUTL TradingView

BioNTech Pact and Stock Sale Infuse Autolus With $600M for Its Cell Therapies MedCity News

Autolus to Present at Upcoming Investor Conferences PR Newswire

Check out Autolus Therapeutics PLC's stock price (AUTL) in real time CNBC

Blackstone bets on Autolus' CD19 CAR-T in $250M deal, clearing path to pivotal readout in 2022 Fierce Biotech

UCL cancer immunotherapy company, Autolus, launches with £30m investment | UCL News - UCL University College London